Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Oral N-Acetylcysteine on Diabetic Macular Edema

3 de noviembre de 2026 actualizado por: Khadija Ahmed Mhrose Glal

Effect of Oral N-Acetylcysteine on Diabetic Macular Edema in Type 2 Diabetic Patients With Diabetic Retinopathy

Diabetic retinopathy (DR) is one of the leading causes of preventable visual impairment among working-age adults, with diabetic macular edema (DME) representing one of its most important vision-threatening complications. Diabetic macular edema develops when diabetes-associated retinal vascular dysfunction leads to disruption of the blood-retinal barrier (BRB), allowing fluid and plasma components to accumulate within the retinal tissue and impair macular function. The development and persistence of DME involve a complex interplay between vascular, inflammatory, metabolic, and oxidative mechanisms.

Hyperglycemia is a central driver of the molecular abnormalities underlying diabetic retinal injury. Chronic exposure to elevated glucose activates several interrelated pathways, including the polyol, advanced glycation end-products (AGEs), protein kinase C (PKC), and hexosamine pathways. These metabolic disturbances promote the generation of reactive oxygen species (ROS), inflammatory signaling, endothelial dysfunction, and progressive impairment of the retinal neurovascular unit. Together, these processes contribute to damage to endothelial cells, pericytes, Müller cells, and other retinal components, ultimately compromising the integrity of the BRB.

Oxidative stress is therefore considered an important component of the pathophysiology of DR and DME. Excessive ROS production can directly damage cellular structures and can also amplify inflammatory and angiogenic signaling. This may increase the expression of several mediators implicated in retinal vascular dysfunction. The resulting vascular instability and increased permeability facilitate fluid extravasation into the retinal layers and contribute to the development and progression of DME.

Malondialdehyde (MDA), a product of lipid peroxidation, is widely used as a marker of oxidative damage. Increased MDA concentrations have been reported in patients with diabetic retinopathy and have been associated with the presence or severity of retinal disease, supporting the involvement of oxidative stress in diabetic retinal injury. Assessment of MDA may therefore provide a useful systemic indicator of the oxidative component of the disease process.

Angiopoietin-2 (Ang-2), an important regulator of vascular stability, has also been implicated in diabetic retinal vascular dysfunction. Increased Ang-2 can promote endothelial destabilization and enhance vascular permeability, particularly in the presence of inflammatory and VEGF-related signaling. Thus, oxidative stress and angiogenic dysregulation may represent interconnected components of the vascular injury that ultimately leads to BRB disruption and retinal fluid accumulation.

Current management of DME relies predominantly on ophthalmic interventions, with corticosteroids and laser photocoagulation having roles in selected clinical settings. Although these approaches have substantially improved visual and anatomical outcomes, persistent or recurrent edema occurs in a proportion of patients, reflecting the multifactorial nature of DME and the involvement of various pathways.

N-acetylcysteine (NAC) is a thiol-containing compound and a precursor of L-cysteine and reduced glutathione. In addition to its established mucolytic properties, NAC has antioxidant activity through direct scavenging of reactive oxygen species and, importantly, through restoration of intracellular glutathione availability. Its ability to modulate oxidative stress has led to extensive investigation of NAC in a variety of clinical conditions characterized by oxidative and inflammatory injury.

Experimental evidence suggests that attenuation of oxidative stress with NAC may reduce diabetes-related retinal injury and suppress the expression of vascular and inflammatory mediators, including VEGF and intercellular adhesion molecule-1 (ICAM-1). However, the potential clinical relevance of oral NAC in patients with diabetic retinal disease remains insufficiently characterized.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

50

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Damietta, Egipto
        • Reclutamiento
        • Al-Azhar Hospital, Damietta
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

19 años a 69 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patients with type 2 diabetes mellitus
  • Adults aged >18 and <70 years.
  • Patients of either sex.
  • Patients with center-involving diabetic macular edema (CI-DME) with best-corrected visual acuity of 20/25 or better in the study eye and who are considered eligible for observation without immediate anti-VEGF treatment according to predefined ophthalmological criteria.
  • Clear ocular media allowing good quality OCT macula imaging.

Exclusion Criteria:

  • Presence of ophthalmic diseases other than diabetic retinopathy that may affect macular thickness or visual function (Age-related macular degeneration, epiretinal membrane, vitreomacular traction, significant cataract affecting visual assessment, retinal vein occlusion, uveitis, glaucoma, etc.)
  • Pregnancy or breastfeeding.
  • Current use of systemic antioxidant supplements or antioxidant therapy that could interfere with the study outcomes.
  • History of ocular surgery or laser.
  • Systemic diseases affecting retinal microvasculature other than diabetes (e.g., uncontrolled hypertension, vasculitis).
  • Poor image quality (media opacity, interferes with OCT imaging).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Sin intervención: Control
Comparador activo: NAC group

N-acetylcysteine (NAC) at a total daily dose of 1200 mg, administered as 600 mg twice daily

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline in Central Subfield Thickness (CST) Measured by Spectral-Domain Optical Coherence Tomography (SD-OCT)
Periodo de tiempo: 3 months

Central subfield thickness (CST), defined as the retinal thickness within the central 1-mm subfield centered on the fovea, will be measured using spectral-domain optical coherence tomography (SD-OCT; DRI OCT Triton, Topcon, Japan). The change in CST from baseline to the end of the 3-month intervention period will be evaluated.

3 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline in Serum Malondialdehyde (MDA) Concentration
Periodo de tiempo: 3 months

Serum malondialdehyde (MDA), a biomarker of oxidative stress, will be measured at baseline and at the end of the 3-month intervention period. The change in serum MDA concentration from baseline to 3 months will be assessed.

3 months
Change from Baseline in Serum Angiopoietin-2 (Ang-2) Concentration
Periodo de tiempo: 3 months

Serum angiopoietin-2 (Ang-2), a biomarker of vascular destabilization and angiogenic signaling, will be measured at baseline and at the end of the 3-month intervention period. The change in serum Ang-2 concentration from baseline to 3 months will be assessed.

3 months
Change from Baseline in Best-Corrected Visual Acuity (BCVA) Measured Using a Standardized Tumbling E Chart
Periodo de tiempo: 3 months

Best-corrected visual acuity (BCVA) will be assessed using a standardized Tumbling E chart at a distance of 6 meters with appropriate refractive correction. Visual acuity will be recorded according to the predefined chart scoring system and converted to logarithm of the minimum angle of resolution (logMAR) for statistical analysis. The change in BCVA from baseline to 3 months will be evaluated.

3 months
Number of Participants Requiring Rescue Therapy for Diabetic Macular Edema During the Study Period
Periodo de tiempo: 3 months

The number of participants requiring rescue ophthalmological treatment due to clinically significant visual deterioration or worsening of diabetic macular edema during the 3-month follow-up period will be recorded. Rescue treatments may include anti-VEGF therapy, intravitreal corticosteroids, or laser treatment, according to the treating ophthalmologist's clinical judgment and predefined study criteria.

3 months
Number of Participants Experiencing at Least One Adverse Event
Periodo de tiempo: 3 months

The number of participants experiencing at least one adverse event during the intervention period will be recorded. Adverse events will be monitored through weekly telephone follow-up and mont

3 months
Number of Participants Experiencing at Least One Serious Adverse Event
Periodo de tiempo: 3 months

The number of participants experiencing at least one serious adverse event during the intervention period will be recorded and documented, with appropriate clinical management and assessment of the possible relationship to the study medication.

3 months
Number of Participants Discontinuing Study Medication Due to Adverse Events or Intolerance
Periodo de tiempo: 3 months

The number of participants who discontinue the study medication because of adverse events, intolerance, or safety concerns during the intervention period will be recorded.

3 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

28 de octubre de 2026

Finalización primaria (Estimado)

1 de octubre de 2027

Finalización del estudio (Estimado)

1 de octubre de 2027

Fechas de registro del estudio

Enviado por primera vez

28 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

3 de noviembre de 2026

Publicado por primera vez (Actual)

4 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

4 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

3 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NAC&DME

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .